Bayer down as court orders it to pay $2.25 bln in latest Roundup trial
** Shares in Bayer BAYGn.DE fall 5% in early Frankfurt trade after it was ordered to pay $2.25 bln to a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller
** A jury in the Philadelphia Court of Common Pleas on Friday found that John McKivision's non-Hodgkin's lymphoma resulted from the use of Roundup for yard work over several years
** "This is a big initial damages award, and likely negative for shares. But the award is likely to be cut on appeal, in my view," says Sebastian Bray from Berenberg
** "The example of the 2020 Pilliod case jumps to mind – an initial USD2bn verdict was cut to USD87m. Bayer has won 10 of 16 recent glyphosate trials, with the next case due to take place in Delaware state court in February," Bray adds
** The German group's shares had fallen 3.9% YTD as of Friday's close
Reporting by Mateusz Dobrzyniewski
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
